LRRC50 anticorps (N-Term)
Aperçu rapide pour LRRC50 anticorps (N-Term) (ABIN631930)
Antigène
Voir toutes LRRC50 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- N-Term
-
Specificité
- LRRC50 antibody was raised against the N terminal of LRRC50
-
Purification
- Affinity purified
-
Immunogène
- LRRC50 antibody was raised using the N terminal of LRRC50 corresponding to a region with amino acids LNDTLYLHFKGFDRIENLEEYTGLRCLWLQSNGIQKIENLEAQTELRCLF
-
-
-
-
Indications d'application
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. -
Commentaires
-
LRRC50 Blocking Peptide, (ABIN5614577), is also available for use as a blocking control in assays to test for specificity of this LRRC50 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of LRRC50 antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- LRRC50 (Leucine Rich Repeat Containing 50 (LRRC50))
-
Autre désignation
- LRRC50
-
Sujet
- LRRC50 contains 6 LRR (leucine-rich) repeats. It is proposed that LRRC50 to be a novel candidate gene for human cystic kidney disease, involved in regulation of microtubule-based cilia and actin-based brush border microvilli.
-
Poids moléculaire
- 80 kDa (MW of target protein)
Antigène
-